INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$0.62
-0.04 (-6.22%)
▼
5d:
-19.19%
30d:
-27.65%
90d:
-49.59%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 11, 2026
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $0.61, which is considered oversold relative to its 30-day fair value range of $0.73 to $0.90.
Technical Outlook: Technically, INM is in a strong downtrend. Immediate support is located at $0.59, while resistance sits at $0.93. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: INM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+2949.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INM is in a strong downtrend. Immediate support is located at $0.59, while resistance sits at $0.93. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: INM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+2949.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.73 -
$0.90
Company Quality Score
52/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-6.2%)
- BULLISH: Trading 2949.7% below Wall St target ($20.00)
- CAUTION: 5-day price weakness (-19.2%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$0.73 -
$0.90
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.59
Resistance Level
$0.93
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Wall Street Target
$20.00
(+2949.7%)
Revenue Growth (YoY)
-26.2%
Profit Margin
-170.1%
Share & Embed Analysis
Last updated: March 30, 2026 5:00 PM ET
Data refreshes hourly during market hours. Next update: 6:00 PM
Data refreshes hourly during market hours. Next update: 6:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
